RxDoctor Payments Data

Tracy Hutchings, OD

Optometrist · Scottsdale, AZNPI 1487236469

Payments from drug & device makers

$5,714in general payments, 2019–2025

Across 129 payments — averaging $44.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$943
  • Alcon$847
  • Biotissue Holdings Inc.$779
  • AbbVie$582
  • Tarsus Pharmaceuticals, Inc.$406
  • Apellis Pharmaceuticals, Inc.$282
  • plus $2K from 13 others

What the payments were for

  • Food & beverage$5,714100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,714 in reported general payments places this provider in the 90th percentile of 1,134 optometrist providers in Arizona.

See all optometrist providers in Arizona

Medicare billing

Part B allowed, 2024
$155,869
Medicare patients
720
Services billed
1,733

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine66$70,396
XiidraLifitegrast58$61,386
LumiganBimatoprost48$27,343
Prednisolone Acetate228$17,420
Cyclosporine17$12,396
RocklatanNetarsudil Mesylat/Latanoprost35$11,882
MieboPerfluorohexyloctane/Pf11$8,343
SimbrinzaBrinzolamide/Brimonidine Tart29$7,716
CombiganBrimonidine Tartrate/Timolol14$7,023
VyzultaLatanoprostene Bunod11$5,436
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol28$4,088
Latanoprost376$3,476
Cyclopentolate Hcl40$2,257
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat117$2,159
Travoprost13$2,020

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$582$104,762128 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta$943$75,16580 claims
AlconSimbrinza$847$7,71629 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,134 optometrist providers in Arizona.

Other optometrist in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →